In 1963 Jean Bernard introduced the concept of “geographic hematology” and distinguished 2 branches, i.e., “ethnic hematology,” which deals with differences between populations, and “environmental hematology,” which considers factors such as food habits, infections, and others. Both of these branches have implications in the distribution of hematological diseases worldwide. In comparison with Caucasian populations, in Mexico a significantly higher prevalence of acute lymphoblastic, acute promyelocytic, and acute megakaryoblastic leukemias has been described. The rate of chronic myeloid leukemia seems to be as high as that reported in Caucasian populations, while other myeloproliferative neoplasias are significantly less frequent in Mexico. Significantly lower prevalences of hairy cell leukemia, chronic lymphocytic leukemia, multiple myeloma, and Waldenström’s macroglobulinemia have been reported from Mexico. Regrettably, the influence of drug companies interested in selling their new and expensive drugs has resulted in both overdiagnosis of some diseases and overidentification of the refractory forms of some of these conditions to justify the use of unnecessary drugs.

Keywords:
Geographic hematology, Mexico, Overdiagnosis
1.
Mousavi SM, Hemminki K: Cancer incidence, trends, and survival among immigrants to Sweden: a population-based study. Eur J Cancer Prev 2015; 24(suppl 1):S1–S63.
2.
Weiss NS: Geographical variation in the incidence of the leukaemias and lymphomas. Natl Cancer Inst Monogr 1979; 139–142.
3.
Lim JY, Bhatia S, Robison LL, Yang JJ: Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukaemia. Cancer 2014; 120: 955–962.
4.
Ruchlemer R, Polliack A: Geography, ethnicity and “roots” in chronic lymphocytic leukaemia. Leuk Lymphoma 2013; 54: 1142–1150.
5.
De Braekeleer M, De Braekeleer E, Douet-Guilbert N: Geographic/ethnic variability of chromosomal and molecular abnormalities in leukaemia. Expert Rev Anticancer Ther 2015; 15: 1093–1102.
6.
Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI: Incidence rates of the major leukaemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma 2006; 47: 2365–2370.
7.
Ruiz-Argüelles GJ, Lopez-Martinez B, Lobato-Mendizabal E, Ruiz-Delgado GJ: An addition to geographic haematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos. Int J Haematol 2002; 75: 499–502.
8.
Ruiz-Argüelles GJ: Promyelocytic leukaemia in Mexican mestizos. Blood 1997; 89: 348–349.
9.
Ruiz-Argüelles GJ, Garces-Eisele J, Reyes-Nunez V, Gomez-Rangel JD, Ruiz-Delgado GJ: More on geographic haematology: the breakpoint cluster regions of the PML/RAR alpha fusion gene in Mexican mestizo patients with promyelocytic leukaemia are different from those in Caucasians. Leuk Lymphoma 2004; 45: 1365–1368.
10.
Ruiz-Argüelles GJ, Lobato-Mendizabal E, San-Miguel JF, Gonzalez M, Caballero MD, Ruiz-Argüelles A, et al: Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. Br J Haematol 1992; 82: 671–675.
11.
Lobato-Mendizabal E, Ruiz-Argüelles GJ: Prevalence and features of pre-B-cell acute lymphoblastic leukaemia in Mexico: description of 9 patients. Sangre (Barc) 1991; 36: 1–5.
12.
Ruiz-Argüelles GJ, Cantu-Rodriquez OG, Gomez-Almaguer D, Cortes-Franco J, Gongora-Biachi RA, Pizzuto J, et al: Hairy cell leukaemia is infrequent in Mexico and has a geographic distribution. Am J Haematol 1996; 52: 316–318.
13.
Ruiz-Argüelles GJ, Velazquez BM, Apreza-Molina MG, Perez-Romano B, Ruiz-Reyes G, Ruiz-Argüelles A: Chronic lymphocytic leukaemia is infrequent in Mexican mestizos. Int J Haematol 1999; 69: 253–255.
14.
Ruiz-Argüelles GJ, Ramirez-Cisneros FJ, Flores-Martinez J, Cernuda-Graham MC: Waldenstrom’s macroglobulinemia is infrequent in Mexican mestizos: experience of a haematological diseases referral center. Rev Invest Clin 2000; 52: 497–499.
15.
Gomez-Almaguer D, Marcos-Ramirez ER, Montano-Figueroa EH, Ruiz-Argüelles GJ, Best-Aguilera CR, Lopez-Sanchez MD, et al: Acute leukaemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk 2017; 17: 46–51.
16.
Perez-Saldivar ML, Fajardo-Gutierrez A, Bernaldez-Rios R, Martinez-Avalos A, Medina-Sanson A, Espinosa-Hernandez L, et al: Childhood acute leukaemias are frequent in Mexico City: descriptive epidemiology. BMC Cancer 2011; 11: 355.
17.
Mejia-Arangure JM, Bonilla M, Lorenzana R, Juarez-Ocana S, de Reyes G, Perez-Saldivar ML, et al: Incidence of leukaemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer 2005; 5: 33.
18.
Fajardo-Gutierrez A, Juarez-Ocana S, Gonzalez-Miranda G, Palma-Padilla V, Carreon-Cruz R, Ortega-Alvarez MC, et al: Incidence of cancer in children residing in ten jurisdictions of the Mexican Republic: importance of the cancer registry (a population-based study). BMC Cancer 2007; 7: 68.
19.
Bernaldez-Rios R, Ortega-Alvarez MC, Perez-Saldivar ML, Alatoma-Medina NE, Del Campo-Martinez Mde L, Rodriguez-Zepeda Mdel C, et al: The age incidence of childhood B-cell precursor acute lymphoblastic leukaemia in Mexico City. J Pediatr Haematol Oncol 2008; 30: 199–203.
20.
Tlacuilo-Parra A, Garibaldi-Covarrubias R, Romo-Rubio H, Soto-Sumuano L, Ruiz-Chavez CF, Suarez-Arredondo M, et al: Geographical distribution and cluster detection of childhood leukaemia in the metropolitan area of Guadalajara, Mexico. Rev Invest Clin 2017; 69: 159–165.
21.
Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A: Leukaemia and nutrition. 1. Malnutrition is an adverse prognostic factor in the outcome of treatment of patients with standard-risk acute lymphoblastic leukaemia. Leuk Res 1989; 13: 899–906.
22.
Gómez-Almaguer D, Ruiz-Argüelles GJ, Ponce-de-León S: Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukaemia. Int J Cancer Suppl 1998; 11: 52–55.
23.
Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno JA, Montes-Montiel M, Ruiz-Argüelles GJ: Outcome of adults with acute lymphoblastic leukaemia treated with a pe diatric-inspired therapy: a single institution experience. Leuk Lymphoma 2011; 52: 314–316.
24.
Jaime-Perez JC, Brito-Ramirez AS, Pinzon-Uresti MA, Gutierrez-Aguirre H, Cantu-Rodriguez OG, Herrera-Garza JL, et al: Characteristics and clinical evolution of patients with acute myeloblastic leukaemia in northeast Mexico: an eight-year experience at a university hospital. Acta Haematol 2014; 132: 144–151.
25.
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM: Acute leukaemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119: 34–43.
26.
Forman D, Stockton D, Moller H, Quinn M, Babb P, De Angelis R, et al: Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003; 14: 648–654.
27.
Padilha SL, Souza EJ, Matos MC, Domino NR: Acute myeloid leukaemia: survival analysis of patients at a university hospital of Parana. Rev Bras Haematol Hemoter 2015; 37: 21–27.
28.
Pulcheri W, Spector N, Nucci M, de Morais JC, Pimenta G, de Oliveira HP: The treatment of acute myeloid leukaemia in Brazil: progress and obstacles. Haematologica 1995; 80: 130–135.
29.
Meng CY, Noor PJ, Ismail A, Ahid MF, Zakaria Z: Cytogenetic profile of de novo acute myeloid leukaemia patients in Malaysia. Int J Biomed Sci 2013; 9: 26–32.
30.
Bahl A, Sharma A, Raina V, Kumar L, Bakhshi S, Gupta R, et al: Long-term outcomes for patients with acute myeloid leukaemia: a single-center experience from AIIMS, India. Asia Pac J Clin Oncol 2015; 11: 242–252.
31.
Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM: High frequency of acute promyelocytic leukaemia among Latinos with acute myeloid leukaemia. Blood 1996; 87: 308–313.
32.
Rego EM, Jacomo RH: Epidemiology and treatment of acute promyelocytic leukaemia in latin america. Mediterr J Haematol Infect Dis 2011; 3:e2011049.
33.
Melo RA, de Vasconcellos JF, Melo FC, Machado CG, Lacerda TM, Souto FR: PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukaemia patients. Clin Lab Haematol 2006; 28: 126–129.
34.
De Salvo L, Weir Medina J, Gomez Sanchez O, de Baena ES, de Ramos BU, Guevara J, et al: Acute promyelocytic leukaemia in the west of Venezuela (in Spanish). Sangre (Barc) 1989; 34: 329–331.
35.
Otero JC, Santillana S, Fereyros G: High frequency of acute promyelocytic leukaemia among Latinos with acute myeloid leukaemia. Blood 1996; 88: 377.
36.
Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al: Influence of body mass index on incidence and prognosis of acute myeloid leukaemia and acute promyelocytic leukaemia: a meta-analysis. Sci Rep 2017; 7: 17998.
37.
Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M: Association between increased body mass index and a diagnosis of acute promyelocytic leukaemia in patients with acute myeloid leukaemia. Leukaemia 1997; 11: 1661–1664.
38.
Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MeR, Jacomo RH, et al: Improving acute promyelocytic leukaemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 2013; 121: 1935–1943.
39.
Ruiz-Argüelles GJ, Marín-Lopez A, Lobato-Mendizábal E, Ruiz-Argüelles A, Nichols WL, Katzman JA: Acute megakaryoblastic leukaemia: a prospective study of its identification and treatment. Br J Haematol 1986; 62: 55–63.
40.
Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A: Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995. Am J Haematol 1999; 61: 10–15.
41.
Hernandez-Caballero A, Arellano-Llamas AA, Cruz-Rico J, Ojeda JV, Tuna-Aguilar E, Aguayo-Gonzalez A, et al: Genetic susceptibility variants for chronic lymphocytic leukaemia in Mexican mestizos. Br J Haematol 2015; 169: 909–911.
42.
Boggs DR, Chen SC, Zhang ZN, Zhang A: Chronic lymphocytic leukaemia in China. Am J Haematol 1987; 25: 349–354.
43.
Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, et al: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol 2007; 139: 809–819.
44.
Hungria VT, Maiolino A, Martinez G, Duarte GO, Bittencourt R, Peters L, et al: Observational study of multiple myeloma in Latin America. Ann Haematol 2017; 96: 65–72.
45.
Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, et al: Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007; 120(suppl 12): 40–61.
46.
Benjamin M, Reddy S, Brawley OW: Myeloma and race: a review of the literature. Cancer Metastasis Rev 2003; 22: 87–93.
47.
Hernandez-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ: Systemic immunoglobulin light-chain amyloidosis (AL) in México: a single institution, 30-year experience. Rev Invest Clin 2012; 64(6 Pt 2): 604–608.
48.
Ruiz-Argüelles GJ, Gomez-Rangel JD, Ruiz-Delgado GJ, Aguilar-Romero L: Multiple myeloma in México: a 20-year experience at a single institution. Arch Med Res 2004; 35: 163–167.
49.
Ruiz-Delgado GJ, Gomez Rangel JD: Gamopatía monoclonal de significado indeterminado en mestizos mexicanos: experiencia de una sola institución. Gac Meed Meex 2004; 140: 375–379.
50.
Ruiz-Delgado GJ, Ruiz-Argüelles GJ: Genetic predisposition for monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2008; 83: 601–602; author reply 2–3.
51.
Hungria VTM, Lee JH, Maiolino A, De Queiroz Crusoe E, Martinez G, Bittencourt R, et al: Combined analysis of 3,664 patients with multiple myeloma (MM) from Latin America (LA) and Asia. Blood 2017; 130(suppl 1): 5386.
52.
López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ: A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant 2009; 44: 715–719.
53.
Ruiz-Argüelles GJ, Lopez-Martinez B, Ruiz-Reyes G: Heterozygous beta-thalassemia: not infrequent in Mexico. Arch Med Res 2001; 32: 293–295.
54.
De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M, et al: Beta-thalassemia distribution in the Old World: an ancient disease seen from a historical standpoint. Mediterr J Haematol Infect Dis 2017; 9:e2017018.
55.
Murad H, Moasses F, Dabboul A, Mukhalalaty Y, Bakoor AO, Al-Achkar W, et al: Geographical distribution of beta-globin gene mutations in Syria. Haematology 2018; 1–8.
56.
Reyes Cruz G, Hernandez Acasiete M, Ruiz Reyes G: Identification of a focus of beta-thalassemia in Tamiahua, Veracruz (in Spanish). Rev Invest Clin 1990; 42: 189–192.
57.
Reyes-Nunez V, Garces-Eisele J, Jorge S, Kimura E, Ferreira-Costa F, Sonati Mde F, et al: Molecular characterization of alpha-thalassemia in the Mexican population. Rev Invest Clin 2006; 58: 234–236.
58.
Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998; 9: 717–720.
59.
Muller AM, Ihorst G, Mertelsmann R, Engelhardt M: Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Haematol 2005; 84: 1–12.
60.
Diumenjo MC, Abriata G, Forman D, Sierra MS: The burden of non-Hodgkin lymphoma in Central and South America. Cancer Epidemiol 2016; 44(suppl 1):S168–S177.
61.
Jaime-Perez JC, Gamboa-Alonso CM, Vazquez-Mellado-de-Larracoechea A, Rodriguez-Martinez M, Gutierrez-Aguirre CH, Marfil-Rivera LJ, et al: Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma. Arch Med Res 2015; 46: 454–461.
62.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.
63.
Kusminsky G, Abriata G, Forman D, Sierra MS: Hodgkin lymphoma burden in Central and South America. Cancer Epidemiol 2016; 44(suppl 1):S158–S167.
64.
Rendon-Macias ME, Valencia-Ramon EA, Fajardo-Gutierrez A, Castro-Rios A: Incidence of childhood Hodgkin’s lymphoma in Mexico by histologic subtypes and socioeconomic regions. J Pediatr Haematol Oncol 2016; 38:e97–e101.
65.
Punnett A, Tsang RW, Hodgson DC: Hodgkin’s lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol 2010; 20: 30–44.
66.
Ruiz-Delgado GJ, Gómez-Almaguer D, Tarín-Arzaga LC, Cantú-Rodriguez OG, Urdaneta CA, Rodríguez-Morales U, et al: Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin’s lymphoma in a developing country? Haematology 2012; 17: 193–197.
67.
Ruiz-Argüelles GJ, Katzmann JA, Greipp PR, Marín-López A, González-Llaven J, Cano-Castellanos R: Lymphocyte subsets in patients with aplastic anaemia. Am J Haematol 1984; 16: 267–275.
68.
Ruiz-Argüelles GJ, Ramírez Cisneros FJ, Ruiz-Argüelles A, Pérez-Romano B, Morales-Aceves R: Glycosilphosphatidylinositol-anchored cell surface protein deficiency in Mexican mestizo patients with aplastic anaemia (in Spanish). Rev Invest Clin 1999; 51: 5–9.
69.
Hernández-Reyes J, González-Ramírez MP, Martagón-Herrera N, Rosales-Durón AD, Ruiz-Delgado GJ, Ruiz-Argüelles GJ: Paroxysmal nocturnal hemoglobinuria in México: a 30-year, single institution experience. Rev Invest Clin 2014; 66: 12–16.
70.
Delgado-Lamas JL, López-Karpovitch X, Marín-López A, Romero-García F, Ruiz-Argüelles GJ, Ruiz-Gonzalez DS, et al: Low doses of high-potency antithymocyte globulin (ATG) in severe aplastic anaemia: experience with the Mexican ATG. Acta Haematol 1989; 81: 70–74.
71.
Gómez-Almaguer D, Vázquez-Mellado A, Navarro-Cabrera JR, Abello-Polo V, Milovic V, García J, et al: The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants. Bone Marrow Transplant 2017; 52: 41–46.
72.
Lisker R, Ramirez E, Briceño RP, Granados J, Babinsky V: Gene frequencies and admixture estimates in four Mexican urban centers. Hum Biol 1990; 62: 791–801.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.